

# Nanomaterial toxicology - Finding the best way forward


*Vicki Stone*

*[v.stone@hw.ac.uk](mailto:v.stone@hw.ac.uk)*



Toxicology Award Winner  
2015-16

# Dublin: Ban on coal sales, Sept 01 1999



On cessation of coal sales, the  
death rate decreased.

Cause of death	% drop
Non trauma deaths	5.7
Respiratory deaths	15.5
CV deaths dropped	10.3

= 116 fewer resp deaths/year  
+ 243 fewer CV deaths/year

Clancy et al. 2002  
The Lancet 360: 1210-14

# PM<sub>10</sub>

Particulate matter collected through a 10 µm filter with an efficiency of 50%

Carbon based particles

- Traffic and industrial
- Many ultrafine
- Transition metals

Sulphates/Nitrates


- Traffic/photochemical
- Mainly ultrafine

Wind blown dust

- Mainly coarse




Biological components

- Spores
- Pollen
- Mainly fine and coarse



ie Cocktail. Which component is responsible for the health effects?


# The Ultrafine Hypothesis



Seaton A., MacNee W., Donaldson K., Godden D.  
Particulate air pollution and acute health effects.  
Lancet 1995. 345; 176-178.

# Evidence for Ultrafine Particle effects



Neutrophils in  
bronchoalveolar  
lavage fluid  
 $\times 10^5$



Ferin et al. 1992 Am.J.Respir.Cell  
Mol. Biol. 6: 535-542.




# Inhalation as a route of exposure




Martini. Fundamentals of Anatomy and Physiology,  
7<sup>th</sup> edition, 2006.

# Clearing particles from the lung




# The ultrafine particle hypothesis





# Ultrafine carbon particles induce inflammation



Li *et al.* Thorax 1996, 51; 1216-1222.





# Funding Ultrafine particle Toxicology




**THE COLT FOUNDATION**  
OCCUPATIONAL AND ENVIRONMENTAL MEDICINE

# Model ultrafine particles




# Inducing oxidative stress




Stone *et al.* 1998 TIV 12: 649-659.



# ROS produced by ultrafine particles




Wilson *et al.* 2002 TAP 184: 172-179.




Brown *et al.* 2001 TAP 175: 191-199.

# Surface and cell reactivity


Calcium signalling



NF- $\kappa$ B (p65) immunofluorescence




Control



14 nm CB


Brown *et al.* 2004 AJP 286; L344-L353

# Mechanisms



# How small is nano?

## Natural structures






## Artificial structures



# Definitions

- Nanoscale 1-100nm
- Nano object at least 1 dimension 1-100nm
  - E.g. disc, graphene sheet
- Nanomaterial 2 dimensions 1-100nm
  - E.g. fibre, carbon nanotube
- Nanoparticle all 3 dimensions 1-100nm
  - E.g. sphere or cube



# Nano-scale properties


Altered physicochemical characteristics compared to larger forms or the bulk chemical



goldstriker.co.uk




sigmaaldrich.com




Lee et al. 2008. Angew Chem  
Int Ed 47; 2804-7

Eustis and El-Sayed 2006 Chem Soc Rev 35; 209-17  
Boisselier and Astruc 2009 Chem Soc Rev 38; 1759-82


# The diversity of nanomaterials




C60 Fullerenes




Carbon nanotubes




Nanoparticle gold



ZnO nano flowers




Liposomes



Quantum Dots

- Size, shape, charge...
- Matrices...
- Aged, weathered...
- Released...

# Exposure to nanomaterials




Incidental ↓ Purposeful

Environmental Exposure


- Size, shape, charge...
- Matrices...
- Aged, weathered...
- Released...




# Widening the routes and targets



# Characteristics vs Toxicity




# Size and uptake



Clift *et al.* 2008 TAAP 232; 418-427.

# Surface area

Stone and Kinloch Nanotoxicology (book),  
2007, Ed Monteiro and Tran.



**Diameter**

100  $\mu\text{m}$

10 nm

**Surface area**

0.03  $\text{m}^2/\text{g}$

286  $\text{m}^2/\text{g}$


**% atoms at surface**

0.001 %

10.5 %





# Surface area and reactivity




Duffin *et al.* 2002 *Ann Occup Hyg* 46 [suppl 1]; 242-245.


# Fibre induced disease




# Carbon nanotube frustrated phagocytosis



Asbestos




MWCNT




Boyles et al. 2015 Toxicology In Vitro 29

# MWCNT induced pathology



Poland *et al.* 2008 Nature Nanotech 3, 423-428.


# Characteristics vs Toxicity





# Research prioritization to develop an Intelligent Testing Strategy

- **Short term** - understanding of the connections between physicochemical, exposure and hazard IDs to enable **grouping/ ranking**.
- **Longer term** - development of **modelling** approaches for RA with a continual reduction in testing.
- In the **distant future** RA based on modelling and extrapolations and only if additional information is required with focused **physicochemical, exposure and hazard testing**.



## Hazard - final recommendations

- Develop more appropriate **dose metrics** for **dosimetry** studies.
- Determine the **mode of action** and identify reliable **biomarkers**.
- Assess the **bioavailability** and **toxicokinetics**.
- **Standard protocols; *in vitro* and *in vivo*, short and long term**
- Additional **time course** knowledge; **rapid/delayed, reversible/irreversible**
- **Population effects** and **biomagnification**.
- *In vitro* and *in vivo* **models of susceptibility**
- **New tests should**, become **HTP** and eventually *in silico*.
- Future Hazard ID's will become focused as *in silico* approaches develop.
- The *in silico* models should aim to **extrapolate knowledge** across **NMs, target tissues and taxa**.

# Hazard Priorities



Short-term


Mid-term

Long-term





Distant

Stone et al. 2014  
Part Fibre Toxicol 11, 9.

ITS NANO




# How relevant are in vitro models?





# Liver inflammatory gene expression I.V. vs Gavage

i.v. Ag (250 µg/kg)



Gavage Ag 250 µg/kg

Ag 250

tissue	liver	intestine	PPs
gene	gavage	gavage	gavage
FasL			
GSH Pox			
IL-1b			
IL-1R1			
IL-10			
MCP-1			
MIP-2			
TNF			



# Understanding Limitations

- Can a culture of hepatoma cells *in vitro* be used to predict liver responses to nanomaterials?
  - Very good at predicting liver responses to injected Ag, TiO<sub>2</sub> and Au
  - OK at predicting liver responses to pulmonary delivered Ag, TiO<sub>2</sub>, MWCNT and ZnO
  - Poor at predicting liver responses to ingested NP
- Intravenous— particles direct into plasma,
- Inhaled – particles become coated in lung lining fluid
- Ingested – particles modified by gut contents
- *In vitro* – particles become coated in medium components

# Toxicology model development




Barbara Rothen-  
Rutishauser



Hans Bouwmeester

# Ecotoxicology of nanomaterials



Teresa Fernandes



# CuO nanoparticle – Industrial collaboration

## Tiered strategy

Stage 1: Identify existing data

Stage 2: Prioritise NM

lacking data,  
likely to be toxicity due to chemistry,  
potential for exposure and  
high volume of use

Stage 3: Assess toxicity *in vitro* with  
macrophages and hepatocytes, compared to  
other nanomaterials and relevant salts.

Stage 4. Use *in vitro* data to design dose  
range for rodent inhalation study




CuO



# CuO nanoparticle – Industrial collaboration

## Tiered strategy results pristine CuO

- Relatively toxic *in vitro* compared to other NM and Cu salts
- Produced inflammation in lung at day 6
- Inflammation largely resolved by day 28, but small elevation of macrophages remains



# CuO nanoparticle – in polymer matrix

- Within product, CuO NPs are embedded in a polymer matrix
- Impossible to generate fragmented particles at room temperature.
- Only possible to generate fragmented particles in very cold conditions while wet.
- This suggests exposure to fragmented particles containing CuO NPs is likely to be low or unlikely
- Therefore risk to consumers/workers once incorporated should be low
- Currently no plans to assess toxicity of fragmented particles.

Details	Label	BMD <sub>20</sub>
Pristine	CuO	33.2
Buffer	101	18.7
Citrate	102	25.7
PVP	103	16.6
PEI	104	20.4
Ascorbate	105	64.8



Phosphate buffer

Surface modification

BMD<sub>20</sub> Bench mark dose 20 %

20% increase in toxicity over the control value


PVP Polyvinylpyrrolidone

PEI Polyethylenimine

## Using nanomaterials to target TB

- Pathogenic *Mycobacterium* species are slow growing, difficult and expensive to culture *in vitro*.
- Surrogate organism: *Mycobacterium avium* subsp. *paratuberculosis* (*Map*) which causes paratuberculosis or Johnes disease in ruminants.
- Use a *K10 Map* GFP organism to generate fast (7 day vs 7 weeks) fluorescence based assay for assessing efficacy of antibiotics.
  - Donnellan et al. 2015 Nanotoxicology

# Using nanomaterials to target TB



\* $\beta$  represents the change in fluorescence (representing mycobacterial growth) per day

\*\*Each point displaying 2\* the SEM (n=min of 3)


(Donnellan et al., Nanotoxicology 2015)




# Solid Drug Nanoparticles



Andrew Owen



# Colocalisation of Mtb and Solid Drug Nanoparticles





J774 murine macrophage cell line


Blue – DAPI stain of DNA

Green – K10 Map GFP

Red – SDN rifampicin



# Intracellular killing of K10 Map GFP by SDN Rifampicin



# Summary

- Factors influencing toxic potential include size, shape, composition, charge, dissolution....
- Toxicity involves promoting inflammation via oxidative stress and intracellular signalling via calcium
- Intelligent testing strategies are needed to reduce testing
- Toxicity information can be used to prioritise decision making for produce us and for design
- Nanomaterials can be used to target mycobacterial




# Funding

THE COLT FOUNDATION  
OCCUPATIONAL AND ENVIRONMENTAL MEDICINE



Joint Environment and  
Human Health  
Programme (UK)



**CARNEGIE TRUST**

[v.stone@hw.ac.uk](mailto:v.stone@hw.ac.uk)



# Acknowledgements

## Current colleagues

Teresa Fernandes

[Helinor Johnston](#)

[David Brown](#)

John Cherrie

Ted Henry

Mark Hartl

[Matthew Boyles](#)

Mona Connolly

Nilesh Kanase

[Samantha Donnellan](#)

Krystyna Maciaszek

[Daniele Pantano](#)

Valentina Ricottone

Faisal Alqahtani

Angela Kaempfer

Leah Powell

## Former PhD students

Martin Wilson

[Martin Clift](#)

Colin Dick

Lynda Anderson

Philipp Rosenkranz

Elisa Couto Gomez

Fan Zhang

Francesca Broggi

Ali Kermanidazeh

Eva Gubbins

Gary Hutchison

Peter Barlow

Rodger Duffin

Deon Hildebrand

## RIVM

[Flemming Cassee](#)

[Ilse Gosens](#)

Wim de Jong

## Edinburgh University

Ken Donaldson

Mark Miller

## IOM

Rob Aitken

[Lang Tran](#)

Steve Hankin

Craig Poland

Bryony Ross

Sheona Peters

Peter Ritchie

Laura MacCallum

Julia Varet

## Former colleagues

Lorna Proudfoot

Kleanthis Fytianos

Fahran Khan

Morag Prach

Lesley Munro


[v.stone@hw.ac.uk](mailto:v.stone@hw.ac.uk)

THANK  
You!





# The Ultrafine Hypothesis + oxidants




Li *et al.* Environmental Health Perspectives 1997, 105 (suppl 5); 1279-1283.

# The ultrafine particle hypothesis



Seaton A., MacNee W., Donaldson K., Godden D. Particulate air pollution and acute health effects. Lancet 1995. 345; 176-178.


Lung inflammation (neutrophils  $10^5$ )




Ferin et al. 1992 Am.J.Respir.Cell Mol. Biol. 6: 535-542.




# Manipulate NM to reflect route of entry



# Trying to visualise the size of ultrafine particles






NANOTOX 2008,  
Zurich



# Frustrated phagocytosis



Enhanced ROS production

- Antimicrobial function
- Continued production leads to cell activation and tissue damage
- Cell activation leads to cytokine/chemokine production and the recruitment of more inflammatory cells

# Adverse health effects of PM<sub>10</sub>

